The United States Food and Drug Administration (USFDA) has granted final approval to Zydus Lifesciences for Sirolimus Tablets, 1 mg and 2 mg (USRLD: Rapamune Tablets). Rapamune is an anti-rejection medication used to prevent rejection in people 13 and older who have received a kidney transplant. It is also used to treat lymphangioleiomyomatosis, a rare lung disorder that primarily affects women of childbearing age. The drug will be produced at the group’s Moraiya formulation manufacturing facility.
Shopping Cart